Sorriso Pharmaceuticals Presents Positive SOR102 Phase 1b Ulcerative Colitis Data at ECCO Conference
Data from Oral Biologic Show Promising Safety and Efficacy; SOR102 Activity Across Multiple Endpoints Supports Phase 2 Development SALT LAKE CITY, UT, UNITED STATES, February 27, 2025 /EINPresswire.com/ -- Sorriso Pharmaceuticals, a …